Market capitalization | $2.64m |
Enterprise Value | $4.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.16 |
P/S ratio (TTM) P/S ratio | 0.10 |
P/B ratio (TTM) P/B ratio | 0.37 |
Revenue growth (TTM) Revenue growth | -49.41% |
Revenue (TTM) Revenue | $25.47m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Molecular Templates, Inc.:
1 Analyst has issued a forecast Molecular Templates, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 25 25 |
49%
49%
|
|
Gross Profit | 20 20 |
52%
52%
|
|
EBITDA | -14 -14 |
62%
62%
|
EBIT (Operating Income) EBIT | -19 -19 |
58%
58%
|
Net Profit | -16 -16 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. Molecular Templates was founded by Eric E. Poma, Jean Gariépy and Leigh Revers on October 17, 2001 and is headquartered in Austin, TX.
Head office | United States |
CEO | Eric Poma |
Employees | 62 |
Founded | 2000 |
Website | www.mtem.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.